newsfilter
← Latest News
GlobeNewswire·

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

  • Genmab A/S disclosed transactions made by managerial employees & their closely associated persons on November 11, 2026, in compliance with EU Market Abuse Regulation.
  • The company holds power of attorney from these individuals to publish their trading activity in Genmab shares.
  • Genmab is an international biotechnology firm founded in 1999, headquartered in Copenhagen, Denmark, with operations in North America, Europe & Asia Pacific.
  • The company's science powers eight approved antibody medicines & advances a late-stage clinical pipeline using formats like bispecific antibodies & antibody-drug conjugates.
  • Contact persons for inquiries include Marisol Peron (Senior Vice President, Global Communications & Corporate Affairs) & Andrew Carlsen (Vice President, Head of Investor Relations).
  • The announcement includes forward-looking statements regarding future results, risks related to clinical development, manufacturing, market acceptance, & intellectual property protection.
  • Genmab owns trademarks including Genmab®, HuMax®, DuoBody®, HexaBody®, DuoHexaBody®, HexElect®, & KYSO®.
  • The company's CVR number is 2102 3884 & its LEI Code is 529900MTJPDPE4MHJ122.
  • A detailed attachment titled "111126_CA48_Managerial Employee Transactions" accompanies this disclosure.
Company
Genmab A/S
Keywords
Copenhagen Stock Exchange:GMAB, Genmab A/S